LAPINJECT VHD

Main information

  • Trade name:
  • LAPINJECT VHD
  • Pharmaceutical form:
  • Suspension for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • LAPINJECT VHD
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Rabbit haemmorhagic disease virus vaccine
  • Therapeutic area:
  • Rabbit

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0163/001
  • Authorization date:
  • 13-02-2012
  • EU code:
  • FR/V/0163/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

1/5 Dokument1

ANNEXI

SUMMARYOFPRODUCTCHARACTERISTICS

2/5 Dokument1

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Syncrostim500IUlyophilisateandsolventforsolutionforinjectionforcattleandsheep

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Lyophilisatevialscontains:

Activesubstance:

EquineserumGonadotrophin(eCG,formerlyknownasPMSG)...............500IU

Solventvialcontains:

Benzylalcohol.......................................................................................16.5mg/ml

Reconstitutedsolutionfor1doseof2mlcontains:

Activesubstances

EquineserumGonadotrophin(eCG,formerlyknownasPMSG) 500IU

Excipients

Benzylalcohol 33.0mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Lyophilisateandsolventforsolutionforinjection

Lyophilisate:freeze-driedproductintheformofpowderagglomeratedincotton-likepellets.

Solvent:clearcolourlesssolution.

Reconstitutedsolution:clearcolourlesssolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cattle,Sheep.

4.2 Indicationsforuse,specifyingthetargetspecies

Innoncyclingcattle(cowsandheifers)andinewesandewe-lambs:

Inductionandsynchronizationofoestrusandovulation.Tobeusedincombinationwithaprogestagen.

4.3 Contraindications

Seesection4.7.

4.4 Specialwarningsforeachtargetspecies

None.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

3/5 Dokument1

Incaseofanaphylacticshock,symptomatic treatment(e.g.adrenalineorcorticosteroids)shouldbe

administered.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Careshouldbetakenwhenhandlingtheproducttoavoidself-injection.Incaseofaccidentalself-

injection,seekmedicaladvice,andshowthepackageleaflet.

Washhandsafterhandlingtheproduct.

StudiesinlaboratoryanimalsexhibitedteratogeniceffectsaftertheadministrationofeCG.Pregnant

women,thoseintendingtobecomepregnant,orwhosepregnancystatusisunknown,shouldnotusethe

product.

Accidentalspillageontheskinshouldbewashedoffimmediatelywithsoapandwater.

4.6 Adversereactions(frequencyandseriousness)

eCGisanexogenousproteinforspeciesotherthanequine.Therefore,antigen-antibodyreactionsmay

result.Inveryrarecases,repeatedadministrationsofeCGcanprovokeanaphylacticshock(see

section4.5).

4.7 Useduringpregnancy,lactationorlay

StudiesinlaboratoryanimalshaveshownteratogeniceffectsafteradministrationofeCG.

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduringpregnancyandlactation.

Donotuseduringpregnancy

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Intramuscularuse.

500IUofEquineserumgonadotrophin(eCG)peranimalinoneadministrationcorrespondingto2mlof

thereconstitutedsolution.

Dissolvethelyophilisatewith2mlofsolvent.Mixuntilcompletelydissolvedtoobtainahomogenous

solution.

Thereconstitutedsolutionshouldbeusedimmediately.

Theproductshouldbeadministeredatthetimeoftheprogestagendevicewithdrawal.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Administrationofhigherdosesthanrecommendeddosesmayincreasetheriskoftwinsincattleand

tripletsinsheep.

4.11Withdrawalperiod(s)

Meatandoffal:zerodays

Milk:zerodays

4/5 Dokument1

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:gonadotropins

ATCvetcode:QG03GA03

5.1 Pharmacodynamicproperties

EquineSerumGonadotrophin(eCG,inthepastcalledPMSG)isalargeglycoproteinsecretedduring

pregnancyinthemareanditsstructureissimilartotheendogenousgonadotrophinhormones:FSHand

LH.

eCGexertsitseffectsonFSHandLHreceptorsoftargetcellsdistributedinthegonads:infemales,

eCGsupportstheovarianfollicularmaturationbystimulatingthegrowthanddevelopmentofantral

follicles.Inovineandinnon-cyclingbovinefemale,itsuseisrecommendedafteratreatmentforthe

synchronizationofœstruswithaprogestagen:eCGimprovesfolliclematurationandovulationrateand

allowssynchronizationofovulation.

5.2 Pharmacokineticparticulars

Inplasma,eCGdeclinesbiphasicallywithspeciesterminalhalf-livesof22-64hoursand118-220hours

asmeasuredinsheep(i.v.,i.m.)andcows(i.v.,i.m.)respectively.

eCGismainlydegradedinliverandkidneyandeliminatedintheurine.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Lyophilisate:Mannitol.

Solvent:

Benzylalcohol.

Sodiumchloride.

Waterforinjections.

6.2 Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixedwithother

veterinarymedicinalproducts.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:30months

Solvent:shelf-lifeafterfirstopeningthevial:28days.

Shelflifeafterreconstitutionaccordingtodirections:useimmediately.

6.4.Specialprecautionsforstorage

Lyophilisate:protectfromlight.

Storeinarefrigerator(2

C-8

C)

5/5 Dokument1

6.5 Natureandcompositionofimmediatepackaging

Primarypackaging:

Lyophilisate:

ColourlessglassvialtypeIclosedwithachlorobutylstopperandaluminiumcapsule.

Solvent:

ColourlessglassvialtypeIIclosedwithachlorobutylstopperandaluminiumcapsule.

Packsizes:

Cardboardboxcontaining5vialsoflyophilisateandonevialof10mlsolvent

Cardboardboxcontaining10vialsoflyophilisateand2vialsof10mlsolvent

Cardboardboxcontaining25vialsoflyophilisateandonevialof50mlsolvent

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedproductorwastematerialsshouldbedisposedofinaccordancewithnationalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10 DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

19-6-2018

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Active substance: purified, inactivated foot-and-mouth disease virus strains O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir, SAT2 Saudi Arabia) - Centralised - Renewal - Commission Decision (2018)3891 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2292/R/8

Europe -DG Health and Food Safety